Approval · Notice of Compliance 33700 · 2024
IDACIO: Notice of Compliance 33700
Issued July 23, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33700
- Date
- July 23, 2024
- Company
- Fresenius Kabi Canada LtdToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in formulation
- Canadian reference product
- HUMIRA
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IDACIO | Not yet assigned | — |
Medicinal ingredients
- ADALIMUMAB 40 MG per 0.8ML
- ADALIMUMAB 40 MG per SYR
- ADALIMUMAB 40 MG per PEN